Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
As expected, the baseline BMD and T-scores at all three sites were significantly lower in the denosumab group, the baseline Z-scores were significantly lower at the LS and TH in the denosumab group, while no significant differences were observed for the other parameters.Baseline characteristics of the two groupsDenosumab (N = 23)Controls (N = 23)p-valueSex (M:F)10:1310:13NsAge (years)61.5 (7.2)61.4 (9.0)NsPost-menopausal women910NsBMI (kg/m2)23.1 (1.8)24.3 (4.3)NsT2DM3 (15%)3 (15%)NsHistory of previous haemodialysis14 (61%)17 (74%)NsYears from transplant to baseline DXA; median [IQR]4 [1.5;10]5 [2;11]NsPrevious history of fragility fractures74NsChronic GCs23 (100%)23 (100%)/Treatment with calcimimetics4 (17%)6 (26%)NsTreatment with active vitamin D compounds6 (26%)7 (30%)NsTreatment with active vitamin D analogues00/25OHD (nmol/L)48.6 (26.7)57.2 (37.3)0.067Subjects with 25OHD < 30 nmol/L6 (26%)5 (21%)NsSerum corrected calcium (mg/dL)9.6 (0.5)9.5 (0.7)NsALP (U/L)83.4 (43.5)77.8 (29.1)NsPTH (pmol/L)13.0 (10.1)18.9 (14.8)NsSerum creatinine (mg/dL)1.31 (0.45)1.27 (0.43)NsLS T-score − 2.70 (1.20) − 1.42 (1.70)0.006TH T-score − 2.35 (0.77) − 1.40 (1.16)0.014FN T-score − 2.58 (0.52) − 1.98 (1.04)0.002LS Z-score − 1.62 (1.31) − 0.60 (1.50)0.019TH Z-score − 1.43 (0.53) − 0.61 (0.96)0.001FN Z-score − 2.58 (0.51) − 1.95 (1.02)0.085Number of osteoporotic subjects*22 (95%)9 (39%) < 0.001Ten-year probability of fracture (FRAX ®); median [IQR]16 [10.4 to 21.1]10 [6.3 to 14.5]0.02Data are expressed as mean (SD) or absolute number (percentage). *defined as having a T-score < − 2.5 at least one of the three sites.
Source: Patient Characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Patients were further grouped according to baseline estimated glomerular filtration rate (eGFR), calculated using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, as follows: stage 1, eGFR higher or equal to 90 mL/min/1.73 m2; stage 2, eGFR 60 to 89 mL/min/1.73 m2; stage 3a, eGFR 45 to 59 mL/min/1.73 m2; stage 3b, eGFR 30 to 44 mL/min/1.73 m2.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Long-Term Bone Mineral Density Changes in Kidney Transplant Recipients Treated with Denosumab: A Retrospective Study with Nonequivalent Control Group
Study design awaiting verification · Calcified Tissue International · 2024
Original publication title
Long-Term Bone Mineral Density Changes in Kidney Transplant Recipients Treated with Denosumab: A Retrospective Study with Nonequivalent Control Group
© The Author(s) 2024
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Data on the effectiveness of denosumab on osteoporosis after kidney transplantation are limited. We investigated the long-term bone mineral density (BMD) changes in kidney transplant recipients (KTRs) treated with denosumab compared to untreated KTRs. We enrolled KTRs treated with denosumab 60 mg/6 months for 4 years. An untreated group of sex and age-matched KTRs with a 1:1 ratio was included. The primary outcome was BMD changes assessed by Dual-energy X-ray Absorptiometry over 4 years. Data on serum creatinine, alkaline phosphatase (ALP), parathyroid hormone, and 25-hydroxyvitamin D were collected.
All patients received oral cholecalciferol and calcium supplementation. 23 denosumab-treated KTRs were enrolled, and 23 untreated KTRs. The median time from transplant to the start of denosumab was 4 years (range 0:24). The denosumab group showed a significant increase from baseline in BMD at the lumbar spine (LS) (9.0 ± 10.7%, p < 0.001), and total hip (TH) (3.8 ± 7.9%, p = 0.041). The untreated group showed a significant decrease at all sites (− 3.0 ± 7%, p = 0.041 at the LS; − 6.3 ± 9.2%, p = 0.003 at the TH; − 6.7 ± 9.3%, p = 0.003 at the FN).
The between-group differences in percent BMD changes were statistically significant at all sites. Similar results were found for the respective Z-scores. The ALP serum levels significantly decreased from baseline only in the denosumab group, with a significant between-group difference (p = 0.032). No significant differences in serum creatinine, hypocalcaemic events or acute graft rejection rates were observed. Four years of denosumab therapy were associated with increased BMD in KTRs, while untreated KTRs showed significant BMD losses at all sites.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00223-024-01218-z.
Authors’ abstract
Data on the effectiveness of denosumab on osteoporosis after kidney transplantation are limited. We investigated the long-term bone mineral density (BMD) changes in kidney transplant recipients (KTRs) treated with denosumab compared to untreated KTRs. We enrolled KTRs treated with denosumab 60 mg/6 months for 4 years. An untreated group of sex and age-matched KTRs with a 1:1 ratio was included. The primary outcome was BMD changes assessed by Dual-energy X-ray Absorptiometry over 4 years. Data on serum creatinine, alkaline phosphatase (ALP), parathyroid hormone, and 25-hydroxyvitamin D were collected.
All patients received oral cholecalciferol and calcium supplementation. 23 denosumab-treated KTRs were enrolled, and 23 untreated KTRs. The median time from transplant to the start of denosumab was 4 years (range 0:24). The denosumab group showed a significant increase from baseline in BMD at the lumbar spine (LS) (9.0 ± 10.7%, p < 0.001), and total hip (TH) (3.8 ± 7.9%, p = 0.041). The untreated group showed a significant decrease at all sites (− 3.0 ± 7%, p = 0.041 at the LS; − 6.3 ± 9.2%, p = 0.003 at the TH; − 6.7 ± 9.3%, p = 0.003 at the FN).
The between-group differences in percent BMD changes were statistically significant at all sites. Similar results were found for the respective Z-scores. The ALP serum levels significantly decreased from baseline only in the denosumab group, with a significant between-group difference (p = 0.032). No significant differences in serum creatinine, hypocalcaemic events or acute graft rejection rates were observed. Four years of denosumab therapy were associated with increased BMD in KTRs, while untreated KTRs showed significant BMD losses at all sites.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00223-024-01218-z.
Publication and source details
Original title: Long-Term Bone Mineral Density Changes in Kidney Transplant Recipients Treated with Denosumab: A Retrospective Study with Nonequivalent Control Group
Angelo Fassio; Stefano Andreola; Davide Gatti; Francesco Pollastri; Matteo Gatti; Paolo Fabbrini; Giovanni Gambaro; Pietro Manuel Ferraro; Chiara Caletti; Maurizio Rossini; Ombretta Viapiana; Riccardo Bixio; Giovanni Adami
Calcified Tissue International · 2024
© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Università degli Studi di VeronaOpen access funding provided by Università degli Studi di Verona within the CRUI-CARE Agreement.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T04:15:15.353104+00:00
DOI: 10.1007/s00223-024-01218-z · PMC11153264